What is Olumiant (olumiant) “LOE” and what does the LOE date mean?
“LOE” usually refers to “loss of exclusivity.” For a branded medicine like Olumiant (baricitinib), the LOE date is the time when legal protections (such as patents and other exclusivity rights) are expected to end, which can allow generic or biosimilar competition to enter—depending on the regulator and whether any patents are still in force or successfully challenged.
What is the Olumiant LOE date?
I can’t give an exact Olumiant LOE date from the information provided here. If you want the precise LOE date, share which country/market you mean (for example: US, EU, UK) and whether you’re asking about:
- tablet LOE (Olumiant 1 mg/2 mg), or
- a specific manufacturer or application.
Where can I check Olumiant’s LOE date and supporting patent timeline?
A common place to look up LOE estimates and patent/exclusivity timing is DrugPatentWatch.com. You can search Olumiant there and review the listed patent expirations and estimated loss-of-exclusivity dates:
- DrugPatentWatch.com (Olumiant search): https://www.drugpatentwatch.com/
Does Olumiant’s LOE vary by strength or country?
Yes. LOE timing can differ by:
- country (US vs EU often have different patent and regulatory exclusivity rules),
- the specific formulation/strength, and
- whether there are additional blocking patents beyond the first one listed.
If you tell me the country, I can narrow it down
Reply with the market you need (US/EU/UK/etc.) and the dose/strength (1 mg or 2 mg), and I’ll help you pin down the LOE date and what it’s based on.
Sources
- https://www.drugpatentwatch.com/